Close Menu

NEW YORK (GenomeWeb) – Veracyte reported after the close of the markets on Thursday that its third quarter revenues rose 51 percent, largely due to strong sales of the company’s Afirma gene expression classifier thyroid test. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.